Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rifampicin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: Rifampicin. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-003347-10 Sponsor Protocol Number: PXR-HDL Start Date*: 2017-01-16
    Sponsor Name:Oulu University Hospital, Internal Medicine Research Unit
    Full Title: The effects of PXR activation on HDL-cholesterol
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000632-27 Sponsor Protocol Number: PORT-01 Start Date*: 2022-08-03
    Sponsor Name:Radboud University Medical Center
    Full Title: Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019727-55 Sponsor Protocol Number: MRSA-2010 Start Date*: 2010-08-17
    Sponsor Name:
    Full Title: Eradikeringsbehandling av MRSA- en jämförelse av kombinerad systemisk antibiotikabehandling och lokal mupirocinbehandling med enbart mupirocin för att eradikera MRSA vid svalgbärarskap
    Medical condition: MRSA-bärarskap
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005843-24 Sponsor Protocol Number: RIFA+UDCA Start Date*: 2006-02-23
    Sponsor Name:Hanns-Ulrich Marschall
    Full Title: Studie på effekten av rifampicin och ursodeoxycholsyra på gallipider och deras transport och avgiftning hos patienter med kolesterolgallstenar.
    Medical condition: Gallstone disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003146-36 Sponsor Protocol Number: RIAlta-1 Start Date*: 2023-11-15
    Sponsor Name:Vall d'Hebron Research Institute (VHIR)
    Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis
    Medical condition: Pulmonary and extrapulmonary tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001525-10 Sponsor Protocol Number: bins1 Start Date*: 2013-07-30
    Sponsor Name:Erasmus MC
    Full Title: Studying the metabolism of sorafenib (Nexavar®) by OATP1B blockage in adult cancer patients
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005078-10 Sponsor Protocol Number: FARM7X9F8K Start Date*: 2008-10-20
    Sponsor Name:AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI
    Full Title: RANDOMISED, OPEN-LABEL CLINICAL TRIAL ON THE EFFICACY OF COLISTIN PLUS RIFAMPICIN TREATMENT VERSUS COLISTIN ALONE FOR SEVERE INFECTIONS BY MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII
    Medical condition: Severe nosocomial infections due to multi-drug resistant Acinetobacter baumannii
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021881 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000938-20 Sponsor Protocol Number: 2019-5172 Start Date*: 2021-04-15
    Sponsor Name:Radboudumc
    Full Title: Pharmacokinetic study of minocycline in patients with pulmonary nontuberculous mycobacterial disease
    Medical condition: Pulmonary disease caused by Mycobacterium avium complex. Mycobacterium avium complex is a nontuberculous mycobacterium.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001626-22 Sponsor Protocol Number: RML-TB Start Date*: 2022-03-28
    Sponsor Name:Vall d'Hebron Institute of Research
    Full Title: A Multicentre Controlled Open Randomized Clinical Trial to evaluate the efficacy and safety profile of an anti-TB drug combination based on High Dose Rifampicin, High Dose Moxifloxacin and Linezoli...
    Medical condition: Smear-positive rifampicin-sensitive pulmonary Tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006613-10 Sponsor Protocol Number: TMC207LEP3001 Start Date*: 2024-08-13
    Sponsor Name:Janssen Pharmaceutica NV
    Full Title: A Phase 3, Multicenter, Open-label, Rater-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline for the Treatment of Multibacillary Leprosy When Combined With Rifampicin...
    Medical condition: Multibacillary Leprosy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10024232 Leprosy, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2012-000344-10 Sponsor Protocol Number: Start Date*: 2012-05-24
    Sponsor Name:Medical Research Council [...]
    1. Medical Research Council
    2. Kings College London
    Full Title: Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a randomised controlled trial
    Medical condition: S. aureus bacteraemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    14.1 10021881 - Infections and infestations 10054638 Staphylococcus aureus septicemia LLT
    14.1 10021881 - Infections and infestations 10058863 Staphylococcus aureus bacteraemia LLT
    14.1 10021881 - Infections and infestations 10041943 Staphylococcus aureus septicaemia LLT
    14.1 10021881 - Infections and infestations 10058867 Methicillin-resistant staphylococcal aureus sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003169-20 Sponsor Protocol Number: 20-AOI-03 Start Date*: 2020-10-20
    Sponsor Name:CHU de Nice
    Full Title: Efficacy of dalbavancin during osteo-articular infections associated with hip and knee prostheses
    Medical condition: Osteo-articular infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10075981 Staphylococcus aureus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004011-44 Sponsor Protocol Number: UofATURRIFIC Start Date*: 2020-05-20
    Sponsor Name:The University of Adelaide
    Full Title: A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruri...
    Medical condition: Intrahepatic Cholestasis of Pregnancy (ICP) is an serious liver condition in pregnancy. The main symptom of this is itching. Ursodeoxycholic acid is routinely used to treat cholestasis but is not...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001276-56 Sponsor Protocol Number: AIDA Start Date*: 2014-07-11
    Sponsor Name:North Bristol NHS - Southmead Hospital
    Full Title: A prospective, open label, randomised controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatme...
    Medical condition: Complicated Skin and Skin Structure infections caused by Methicillin Resistant Staphylococcus Aureus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003721-25 Sponsor Protocol Number: High-shortRP Start Date*: 2020-02-03
    Sponsor Name:Region Östergötland
    Full Title: Randomized prospective phase II clinical trial investigating pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in an shortened tuberculosis treatment compared to st...
    Medical condition: Tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005522-22 Sponsor Protocol Number: Rifa-BP Start Date*: 2012-01-23
    Sponsor Name:Oulu University Hospital, Department of Internal Medicine
    Full Title: The effects of PXR activation on blood pressure regulation
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-000471-20 Sponsor Protocol Number: RIPH_2019_01 Start Date*: 2020-11-30
    Sponsor Name:CH Tourcoing
    Full Title: Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-la...
    Medical condition: Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10065011 Prosthesis related infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003786-28 Sponsor Protocol Number: PERC2015 Start Date*: 2016-01-19
    Sponsor Name:Radboudumc
    Full Title: Pulmonary NTM disease: A regimen of ethambutol and azithromycin with as adjunctive rifampicin vs clofazimine.
    Medical condition: Fibrocavitary pulmonary disease caused by M.avium complex
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023776-52 Sponsor Protocol Number: Lisette-1 Start Date*: 2011-01-19
    Sponsor Name:
    Full Title: Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002871-32 Sponsor Protocol Number: Rifabupre Start Date*: 2012-08-28
    Sponsor Name:Turku University hospital
    Full Title: Effects of rifampicin on the pharmacokinetics and pharmacodynamics of sublingual and intravenous buprenorphine: A four-phase cross-over study in healthy subjects.
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:53:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA